INT191253

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 2005
Last Reported 2009
Negated 0
Speculated 1
Reported most in Body
Documents 13
Total Number 15
Disease Relevance 10.05
Pain Relevance 1.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (DDR1) cell adhesion (DDR1) plasma membrane (DDR1)
Anatomy Link Frequency
thyroid 3
fibroblast 3
endothelial cells 2
brain 1
DDR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 24 97.72 Very High Very High Very High
fibrosis 135 95.52 Very High Very High Very High
cytokine 27 86.96 High High
Potency 16 67.44 Quite High
metalloproteinase 21 58.88 Quite High
tolerance 1 20.20 Low Low
Glutamate 5 10.88 Low Low
imagery 17 5.00 Very Low Very Low Very Low
Inflammation 15 5.00 Very Low Very Low Very Low
corticosteroid 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Thyroid Neoplasm 981 99.92 Very High Very High Very High
Pancreatic Cancer 74 99.26 Very High Very High Very High
Death 76 98.68 Very High Very High Very High
Carcinoma 121 97.40 Very High Very High Very High
Brain Death 14 97.28 Very High Very High Very High
Disease 205 97.04 Very High Very High Very High
Cancer 499 96.80 Very High Very High Very High
Pulmonary Fibrosis 45 95.52 Very High Very High Very High
Apoptosis 26 94.88 High High
Breast Cancer 169 88.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The concept of DCD is a creative interpretation of the DDR [17], equating the aftermath of cardiac death with the presence of brain death.
Negative_regulation (interpretation) of DDR in brain associated with brain death and death
1) Confidence 0.25 Published 2005 Journal Crit Care Section Body Doc Link PMC1414041 Disease Relevance 1.39 Pain Relevance 0
There are also limitations in our ability to subsequently evaluate RTK and ER signalling aspects emerging from experimental studies in clinical disease and to rapidly translate findings into clinically useful biomarkers and targets for new drug development.
Negative_regulation (evaluate) of RTK associated with disease
2) Confidence 0.15 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2397525 Disease Relevance 0.70 Pain Relevance 0
Here we analyze the underlying mechanistic cell effects in vitro with respect to the cellular pathway of RTK inhibition and to radiation for the PDGF/PDGFR system in human primary fibroblasts and endothelial cells.


Negative_regulation (inhibition) of RTK in endothelial cells
3) Confidence 0.06 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1458351 Disease Relevance 0.51 Pain Relevance 0.23
Since the signalling pathway in pancreatic cancer is dysregulated at multiple levels, inhibition of only the RTK may be insufficient to alter the chemoresistant nature of pancreatic cancer.
Negative_regulation (inhibition) of RTK associated with pancreatic cancer
4) Confidence 0.06 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727890 Disease Relevance 0.57 Pain Relevance 0
Importantly, the RTK inhibitor significantly inhibited this paracrine radiation-induced fibroblast and endothelial cell activation.


Negative_regulation (inhibitor) of RTK in fibroblast
5) Confidence 0.05 Published 2006 Journal BMC Cancer Section Abstract Doc Link PMC1458351 Disease Relevance 0 Pain Relevance 0.03
Here we investigate in vitro whether primary human endothelial and fibroblast cells are an important primary target of the RTK inhibitor in the context of PDGF signaling.
Spec (whether) Negative_regulation (inhibitor) of RTK in fibroblast
6) Confidence 0.05 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1458351 Disease Relevance 0.24 Pain Relevance 0.08
Interestingly, many of the novel RTK inhibitors, ZD6474, sorafenib, and sunitinib, for example, appear to non-specifically inhibit multiple signaling pathways critical in thyroid carcinogenesis, suggesting a potential synergistic effect to these novel drugs; however, the question of whether this lack of specificity will be advantageous or disadvantageous in the long run for patients remains unanswered.
Negative_regulation (inhibitors) of RTK in thyroid
7) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 0.73 Pain Relevance 0.17
RTK inhibitors are likely to be beneficial for patients with hereditary MTC, where currently there are no effective chemotherapy or radiotherapy options.
Negative_regulation (inhibitors) of RTK associated with thyroid neoplasm
8) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 0.93 Pain Relevance 0.10
ZD6474 (vandetanib) is a low-molecular-weight tyro-sine kinase inhibitor that has demonstrated potent and selective inhibition of RTK in vitro (Carlomagno et al 2002; Wedge et al 2002).
Negative_regulation (inhibition) of RTK
9) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 0.93 Pain Relevance 0.09
Utilizing an orthotopic anaplastic thyroid carcinoma xenograft model in nude mice, Kim et al have shown that sorafenib, a multikinase inhibitor of RTK, VEGFR, and BRAF kinase, inhibits proliferation of ATC cell lines and inhibits tumor angiogenesis via induction of endothelial apoptosis (Kim et al 2007).
Negative_regulation (inhibitor) of RTK in thyroid associated with thyroid neoplasm, cancer and apoptosis
10) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 1.10 Pain Relevance 0
In fact, the aforementioned compound ZD6474 is, in addition to its role in RTK inhibition, a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and EGFR.
Negative_regulation (inhibition) of RTK
11) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621417 Disease Relevance 0.85 Pain Relevance 0.09
Inhibitors of the activated RET proto-oncogene and other RTK inhibitors appear particularly promising, based on the high prevalence of mutated oncogenes and specific expression patterns in MTC [2].
Negative_regulation (inhibitors) of RTK associated with thyroid neoplasm
12) Confidence 0.03 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2798103 Disease Relevance 0.73 Pain Relevance 0
Recently, Kim et al. have shown that sorafenib, a multikinase inhibitor of RTK, VEGFR, and BRAF kinase, inhibits proliferation of ATC cell lines and inhibits tumor angiogenesis via induction of endothelial apoptosis in an orthotopic anaplastic thyroid carcinoma xenograft model in nude mice [20].
Negative_regulation (inhibitor) of RTK in thyroid associated with thyroid neoplasm, cancer and apoptosis
13) Confidence 0.03 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2798103 Disease Relevance 0.86 Pain Relevance 0
Here we analyze the underlying mechanistic cell effects in vitro with respect to the cellular pathway of RTK inhibition and to radiation for the PDGF/PDGFR system in human primary fibroblasts and endothelial cells.


Negative_regulation (inhibition) of RTK in fibroblasts
14) Confidence 0.02 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1458351 Disease Relevance 0.51 Pain Relevance 0.23
Importantly, the RTK inhibitor significantly inhibited this paracrine radiation-induced fibroblast and endothelial cell activation.


Negative_regulation (inhibitor) of RTK in endothelial cell
15) Confidence 0.02 Published 2006 Journal BMC Cancer Section Abstract Doc Link PMC1458351 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox